Navigation Links
Amicus Therapeutics Announces Third Quarter 2007 Financial Results
Date:10/31/2007

ore income

taxes: (9,195) (1,108) (10,303)

Net loss: $(9,195) $ - $ - $(1,108) $(10,303)

Net loss per

share - basic and

diluted: $(0.41) $ - $ - $(0.05) $(0.46)

Weighted

average number

of shares

outstanding: 22,291,832 22,291,832

Table 3

Amicus Therapeutics, Inc. Statement of Operations Information for Three Months Ended September 30, 2006

(In thousands, except share and per share amounts)

Change in

Fair

Value of Preferred

Warrant Stock Stock GAAP as

Non-GAAP Liability Accretion Compensation Reported

Income Statement

Classifications:

Research and

development $(6,239) $ - $ - $(486) $(6,725)

General and

administrative (3,368) (415) (3,783)

Depreciation and

amortization (245) (245)

Interest income 519 519

Interest expense (75) (75)

Change in fair

value of

warrant

liability - (154) (154)

Other expense (1,180) (1,180)

Preferred stock

accretion - (41) (41)

Summary:

Loss before

income taxes: (10,588) (154) (41) (901) (11,684)

Net loss: $(10,588) $ (154) $ (41) $(901) $(11,684)

Net loss per

share - basic'/>"/>

SOURCE Amicus Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , , , There is obviously no single , ... amplifications. For example, , depending on the length and sequence ... can differ from each other. Finding the optimal or the , ... and efficient amplification of a specific target. , ...
... Using Eppendorf Mastercycler gradient , , , , ... NPC Laboratory, Institute of Postgraduate Studies and Research, University , of Malaya, Kuala Lumpur, Malaysia , , ... , , ... , , ...
... Plant RNA, Using the Eppendorf Perfect ... , , , Sonja Vorwerk and ... Zchtungsforschung, Carl-von-Linn , Weg 10, 50829 Cologne, Germany , ... , Barbro Patterson, Eppendorf AG, Germany , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 2Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 3Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 4Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 5Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 2Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 3Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 4Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 5Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 6
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "iPhone 5S ... Technology Report" report to their offering. ... Following the acquisition of AuthenTec in July 2012, ... iPhone 5S. It is currently the only device ...
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... present its fifth annual Regional Policy Award to Ken ... Society,s upcoming conference in Portland, Oregon. The ESA award ... an outstanding record of informing political decision-making with ecological ... prestigious award to Ken Bierly for his long-term commitment ...
... in German . Excitation of neurons ... calcium and potassium through specific channels. Obviously, these channels were ... such channels could have evolved their selectivity has been a ... University of Vienna together with Scientists from Tel Aviv University ...
... older adults especially those who are frail low levels ... The randomized, nationally representative study found that older adults with ... death than people who had higher levels. Overall, people ... than those who were not frail. Frail adults with low levels ...
Cached Biology News:Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 2Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 3Ion selectivity in neuronal signaling channels evolved twice in animals 2Lower vitamin D could increase risk of dying, especially for frail, older adults 2
... high gel-strength agarose suitable for a wide ... constant field to Pulsed Field Gel Electrophoresis ... and exclusion limits, Multi ABgarose can effectively ... times. This in turn means reduced band ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Biology Products: